Englewood, CO — [January 30, 2015] — Swedish Medical Center is the first facility in the Rocky Mountain Region to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF).
“At Swedish Medical Center we are relentlessly passionate about providing the absolute highest quality patient care, and that means having the most advances options available to our patients. Offering CardioMEMS ™ System is an example of the collaboration between our physicians, staff and cardiac leadership to maintain our reputation for being innovators in the quality of life and treatment of heart failure patients,” says Swedish Medical Center CEO, Mary M. White.
The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure.
“This new wireless implantable sensor device is a potential “game changer” and a “paradigm shift” in the care of patients with congestive heart failure. It will allow early detection of changes in the internal fluid balance of a patient with congestive heart failure which will allow adjustments in treatment to be made before fluid retention causes trouble, explains Interventional Cardiologist, Dr. Ira Dauber of Swedish Medical Center.
The CardioMEMS HF System features a sensor that is implanted in the pulmonary artery (PA) during a non-surgical procedure to directly measure PA pressure. Increased PA pressures appear before weight and blood pressure changes, which are often used as indirect measures of worsening heart failure. The new system allows patients to transmit daily sensor readings from their homes to their health care providers allowing for personalized and proactive management to reduce the likelihood of hospitalization.
“Patients with congestive heart failure are prone to fluid retention which is what causes the symptoms of congestion, such as difficulty breathing and leg and body swelling, that characterize congestive heart failure,” says Dauber.
Heart failure occurs when the heart is unable to pump enough blood to meet the body’s demands. According to the Centers for Disease Control and Prevention, more than 5.1 million Americans have heart failure, with 670,000 new cases diagnosed each year. Patients with heart failure are frequently hospitalized, have a reduced quality of life and face a higher risk of death.
The CardioMEMS sensor is designed to last the lifetime of the patient and doesn’t require batteries. Once implanted, the wireless sensor sends pressure readings to an external patient electronic system. There is no pain or sensation for the patient during the readings. The CardioMEMS HF System allows the patients to transmit critical information about their heart failure status to a clinician on a regular basis, without the need for additional clinic or hospital visits. This provides clinicians with the ability to detect worsening heart failure sooner and adjust treatment to reduce the likelihood that the patient will need to be hospitalized.
“I don’t have to worry about my lungs filling up with fluid anymore and I’ll be able to breathe,” says patient Richard Damico.
Data from a clinical trial showed that the CardioMEMS technology reduces heart failure hospital admissions by up to 37 percent. The CHAMPION trial studied the effectiveness of the CardioMEMS HF System in New York Heart Association (NYHA) Functional Classification System class III heart failure patients who had been hospitalized for heart failure in the previous 12 months. Results of the trial demonstrated a statistically significant 28 percent reduction in the rate of heart failure hospitalizations at six months, and 37 percent reduction in heart failure hospitalizations during an average follow-up duration of 15 months.
Roughly 1.4 million patients in the U.S. have NYHA Class III heart failure, and historically these patients account for nearly half of all heart failure hospitalizations. According to the American Heart Association, the estimated direct and indirect cost of heart failure in the U.S. for 2012 was $31 billion and that number is expected to more than double by 2030.
“This new technology continues our commitment to improve the care and quality of life of our patients with congestive heart failure problems. Importantly it empowers the patient to play an active role in their treatment, says Dauber.
The CardioMEMS HF System, from global medical device manufacturer St. Jude Medical, is approved by the U.S. Food and Drug Administration (FDA) for commercial use in the U.S. For more information, visit http://www.heartfailureanswers.com/.
About Swedish Medical Center
Swedish Medical Center in Englewood, Colorado, part of HealthONE, serves as the Rocky Mountain Region’s referral center for neurotrauma and as the region’s first Joint Commission certified Comprehensive Stroke Cen¬ter, a recognized leader in the most advanced stroke care. Swedish offers patients the highest quality care and the most advanced technologies and treatments in nearly every medical specialty and is an eight-time winner of the National Research Corporation Consumer Choice Award and a Top 100 Hospital recognized by Reuters. An acute care hospital with 368 licensed beds, Swedish is located in the south metro Denver area where it has been a proud member of the community for more than 100 years. Annually, Swedish cares for more than 200,000 patients with a team of 2,000 dedicated employees, 500 volunteers and more than 1,300 physicians.
